Montreal, QC – Innodia has been honoured with the prestigious Prix de l’mergence from the Armand-Frappier Foundation. Awarded for the first time in 1994, this prize is presented on a yearly basis to a company having made a significant scientific or technological innovation that represents an exceptional contribution to research or development or that resulted in commercial success.
“We are proud to receive this prestigious award in recognition of our hard work in advancing the understanding and development of type 2 diabetes drugs," says Dr Claude Vezeau, president and CEO of Innodia. "Our dynamic team is committed to keeping the high standards and quality of work acknowledged by this award.”
The Prix de l’mergence was awarded to Innodia for having built a pipeline that includes four novel classes of compounds acting on different molecular targets and representing new approaches for the treatment and prevention of type 2 diabetes.